# Pal-AHK Peptide

> Pal-AHK is a palmitoylated Ala-His-Lys tripeptide that targets topical delivery, hair-follicle signaling, dermal papilla cells, and scalp support.

Canonical: https://pepflow.app/peptides/pal-ahk/

The Hair Signal

Pal-AHK is a palmitoylated form of the tripeptide Ala-His-Lys used in cosmetic and hair-support discussions. Palmitoylation is intended to improve topical compatibility and skin or follicle delivery.

Hair support  Skin appearance

Tier D

Evidence Limited

Safety Limited Data

FDA status Not Approved

Topical 503A Not Listed

Last reviewed August 11, 2026 16 citations [How to read these labels](<https://pepflow.app/peptide-label-legend/>)

## What is Pal-AHK?

Pal-AHK is a palmitoylated form of the tripeptide Ala-His-Lys used in cosmetic and hair-support discussions. Palmitoylation is intended to improve topical compatibility and skin or follicle delivery.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>) [\[2\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Pal-AHK%22&limit=1>)

The key public evidence comes from AHK and copper-complex hair-follicle biology rather than large finished-product clinical trials for every Pal-AHK cosmetic formula.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>) [\[2\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Pal-AHK%22&limit=1>)

Pal-AHK needs distinction from AHK-Cu, GHK-Cu, and Pal-GHK. Related copper-peptide biology can help explain plausibility, but each molecule and formulation has its own evidence limits.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>) [\[2\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Pal-AHK%22&limit=1>)

## What Pal-AHK is investigated for

Pal-AHK evidence is grouped by practical use case and topical route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

### ### Hair growth and dermal papilla cell proliferation Topical 34% Limited

Hair growth is the most direct Pal-AHK signal, but it remains in vitro and preclinical.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>)

#### Human evidence

Controlled topical Pal-AHK human hair-growth trials are not established in the cited literature.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>)

#### Animal / mechanistic evidence

In vitro human hair-growth work with a tripeptide-copper complex supports hair-follicle and dermal-papilla plausibility.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>)

### ### Hair follicle cell survival signaling Topical 28% Limited

Hair follicle survival is a lower-confidence mechanism within hair support.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>)

#### Human evidence

Human anti-apoptotic hair-follicle outcomes for Pal-AHK are not established in the cited literature.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>)

#### Animal / mechanistic evidence

Cell-survival discussion is inferred from the same in vitro hair-follicle biology rather than independent clinical outcomes.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>)

### ### Skin appearance and collagen claims Topical 18% Insufficient

Skin appearance claims remain insufficient until direct Pal-AHK skin data are available.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>) [\[2\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Pal-AHK%22&limit=1>)

#### Human evidence

Controlled Pal-AHK skin appearance, collagen, pigmentation, or microcirculation trials are not established in the cited literature.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>) [\[2\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Pal-AHK%22&limit=1>)

#### Animal / mechanistic evidence

The cited literature is stronger for hair-follicle in vitro biology than for skin collagen or tone outcomes.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>) [\[2\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Pal-AHK%22&limit=1>)

## Evidence snapshot

### Overall confidence

Limited

34%

Pal-AHK remains a preclinical-to-ex vivo cosmetic and hair-follicle rationale. Controlled finished-product scalp and skin outcomes remain limited.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>)

Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.

24%

### Human evidence

Limited

Human ex vivo hair-follicle work supports AHK-related plausibility, but controlled finished-product outcomes are limited.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>)

24%

### Animal / preclinical

Limited

Dermal papilla and follicle biology support the scalp rationale.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>)

34%

### Mechanism support

Limited

AHK-related tripeptide research links hair-follicle elongation, dermal papilla activity, and matrix signaling with scalp-support rationale. Palmitoylation is intended to make the peptide more formulation-friendly.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>)

## Forms & administration

Pal-AHK is tracked as a topical cosmetic peptide ingredient for scalp and skin products. Its protocol context stays topical and formulation-specific rather than systemic.[\[2\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Pal-AHK%22&limit=1>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>)

Topical

## Dosing & protocols

These ranges are general reference points, not personal dosing instructions.

### Typical Range

Topical amounts depend on the finished product.[\[2\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Pal-AHK%22&limit=1>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>)

### Frequency

Usually applied once or twice daily.[\[2\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Pal-AHK%22&limit=1>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>)

### Timing Considerations

Apply in the morning or evening.[\[2\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Pal-AHK%22&limit=1>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>)

### Cycle Length

Track skin or scalp results for several months.[\[2\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Pal-AHK%22&limit=1>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>)

[Full Pal-AHK dosage guide](<https://pepflow.app/peptides/pal-ahk/dosage/>)

## What to expect

### First week

Topical Pal-AHK may change scalp or skin feel, surface smoothness, hydration, and comfort as the routine settles in.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>) [\[2\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Pal-AHK%22&limit=1>)

### Weeks 8-12

Topical scalp or skin use may show changes in shedding, part-line appearance, texture, and skin smoothness in baseline photos.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>) [\[2\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Pal-AHK%22&limit=1>)

### After stopping

Surface cosmetic effects may fade after topical Pal-AHK stops, and hair-cycle changes may drift gradually.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>) [\[2\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Pal-AHK%22&limit=1>)

## Safety profile

Pal-AHK safety is mainly topical cosmetic tolerability: scalp sensitivity, irritation, dryness, formula concentration, and combinations with other actives matter.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>) [\[2\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Pal-AHK%22&limit=1>)

### Common side effects

- Redness / irritation [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>) [\[2\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Pal-AHK%22&limit=1>)
- Scalp itch [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>) [\[2\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Pal-AHK%22&limit=1>)
- Dryness [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>) [\[2\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Pal-AHK%22&limit=1>)

### Cautions

- Sensitive scalp[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>) [\[2\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Pal-AHK%22&limit=1>)
- Broken / infected skin[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>) [\[2\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Pal-AHK%22&limit=1>)
- Copper-peptide overlap[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>) [\[2\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Pal-AHK%22&limit=1>)
- Pregnancy review[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>) [\[2\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Pal-AHK%22&limit=1>)

### What we don't know

Finished-formula concentration, delivery vehicle, copper-peptide overlap, and long-term scalp use are not standardized across products.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>) [\[2\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Pal-AHK%22&limit=1>)

## Who Pal-AHK is not for

Route-specific avoid and medical-review notes:

- **Broken or infected scalp**

  Broken or infected scalp warrants medical review or avoidance for Pal-AHK.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>) [\[2\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Pal-AHK%22&limit=1>)
- **Known allergy to formula components**

  Known allergy to formula components warrants medical review or avoidance for Pal-AHK.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>) [\[2\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Pal-AHK%22&limit=1>)
- **Severe dermatitis flare without clinician review**

  Severe dermatitis flare without clinician review warrants medical review or avoidance for Pal-AHK.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>) [\[2\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Pal-AHK%22&limit=1>)

## Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

### Theoretical interactions

- **Retinoids / acids / exfoliants**

  Retinoids, AHAs, BHAs, scrubs, or irritating scalp actives can compound redness, burning, and barrier disruption; this is a route-specific caution.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>) [\[2\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Pal-AHK%22&limit=1>)
- **Other copper peptides**

  GHK-Cu, AHK-Cu, or multiple copper-peptide products can add copper-burden and irritation uncertainty; this is a product-quality caution.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>) [\[2\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Pal-AHK%22&limit=1>)
- **Minoxidil / topical hair products**

  Minoxidil, alcohol-heavy vehicles, or leave-on hair actives can compound scalp dryness, itch, or irritation; this is a route-specific caution.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>) [\[2\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Pal-AHK%22&limit=1>)

## Regulatory status

### United States

In the U.S. as of 2026-06-21, Pal-AHK may appear in cosmetic-style topical products, but hair-growth or therapeutic claims are drug claims and are not FDA-approved. Cosmetic availability is not the same as drug approval.[\[2\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Pal-AHK%22&limit=1>) [\[3\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[6\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[7\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>)

| Route | FDA drug approval | 503A compounding |
| --- | --- | --- |
| Topical | Not Approved · Pal-AHK is not FDA-approved as a topical drug in the U.S. for the reviewed use; research-market supply and compounding are separate from FDA approval.[\[2\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Pal-AHK%22&limit=1>) [\[3\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[6\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[7\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>) | Not Listed · Pal-AHK is not in the current reviewed 503A compounding bucket for the topical route; compounding status is separate from FDA drug approval.[\[2\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Pal-AHK%22&limit=1>) [\[3\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[6\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[7\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>) |

### Topical

FDA drug approval

Not Approved

Pal-AHK is not FDA-approved as a topical drug in the U.S. for the reviewed use; research-market supply and compounding are separate from FDA approval.[\[2\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Pal-AHK%22&limit=1>) [\[3\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[6\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[7\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>)

503A compounding

Not Listed

Pal-AHK is not in the current reviewed 503A compounding bucket for the topical route; compounding status is separate from FDA drug approval.[\[2\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Pal-AHK%22&limit=1>) [\[3\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[6\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[7\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>)

### International

EU/Europe, UK, Canada, and Australia separate cosmetic products from therapeutic claims. Topical cosmetic availability can follow cosmetic or industrial-chemical frameworks, while hair-growth, skin-lightening, injectable, oral, or disease-treatment claims need market-specific therapeutic-product review.[\[9\]](<https://www.ema.europa.eu/en/medicines>) [\[10\]](<https://products.mhra.gov.uk/>) [\[11\]](<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>) [\[12\]](<https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg>) [\[5\]](<https://www.fda.gov/cosmetics/cosmetics-laws-regulations/fda-authority-over-cosmetics-how-cosmetics-are-not-fda-approved-are-fda-regulated>) [\[13\]](<https://single-market-economy.ec.europa.eu/sectors/cosmetics/legislation_en>) [\[14\]](<https://www.gov.uk/guidance/making-cosmetic-products-available-to-consumers-in-great-britain>) [\[15\]](<https://www.canada.ca/en/health-canada/services/consumer-product-safety/cosmetics/regulatory-information.html>) [\[16\]](<https://www.industrialchemicals.gov.au/cosmetics-and-soap>)

### Sports & competition

WADA has no specific issue for topical cosmetic Pal-AHK in the reviewed materials; S0 is mainly relevant if a product is used as a non-approved systemic pharmacological substance.[\[4\]](<https://ita.sport/resource/wada-2026-prohibited-list/>) [\[2\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Pal-AHK%22&limit=1>) [\[3\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[6\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[7\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>)

## How it works

Pal-AHK is built around an AHK-related tripeptide signal linked with hair-follicle elongation, dermal papilla activity, and extracellular-matrix signaling. In plain terms, the proposed cosmetic mechanism is local scalp or skin support.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>)

Topical delivery is the evidence boundary. Palmitoylation is meant to make the peptide more formulation-friendly, but a serum can only support a local cosmetic claim if the molecule reaches the target tissue at a concentration that matches the evidence. That keeps the mechanism local, cosmetic, and formulation-dependent rather than systemic.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>)

## Research gaps & open questions

What the current literature has not yet settled about Pal-AHK:

01

Controlled trials need to test finished Pal-AHK scalp products in people and measure hair shedding, density, thickness, and growth.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>)

02

Studies should compare concentrations and delivery systems to show how much Pal-AHK reaches the hair follicle and which formulas work best.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>)

03

Combination studies need to show whether Pal-AHK can be safely used with minoxidil, retinoids, or other scalp actives and whether it adds benefit.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>)

## Common questions

### Is Pal-AHK a copper peptide?

No. Pal-AHK is an AHK-derived cosmetic peptide discussed near copper-peptide biology, but exact complex and formula matter.[\[2\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Pal-AHK%22&limit=1>) [\[3\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>)

### Is Pal-AHK FDA-approved for hair growth?

No. Pal-AHK is not FDA-approved in the U.S. as a hair-growth drug; cosmetic topical use is regulated separately from therapeutic claims.[\[2\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Pal-AHK%22&limit=1>) [\[3\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>)

### Is Pal-AHK the same as GHK-Cu?

No. They are related cosmetic-peptide concepts, but they have different sequences, delivery assumptions, and evidence.[\[2\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Pal-AHK%22&limit=1>) [\[3\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>)

## Myths & misconceptions

### Myth

A Pal-AHK serum is a hair-regrowth drug.

### Reality

Topical cosmetic support is not the same as an approved alopecia treatment.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>)

### Myth

More copper peptides are always better.

### Reality

Stacking similar actives can increase irritation and make results harder to interpret.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>)

## History & discovery

Pal-AHK grew from cosmetic peptide attempts to adapt short hair- and matrix-related sequences for topical products. Its history is formulation-led, not systemic drug development. That distinction keeps the origin story tied to evidence strength, route, and product identity rather than broad clinical certainty.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>) [\[2\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Pal-AHK%22&limit=1>)

Human hair-follicle work on an AHK/copper-related tripeptide complex gave the family a scalp-support rationale. That evidence remains local and experimental rather than a drug approval path.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>) [\[2\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Pal-AHK%22&limit=1>)

Palmitoylation made AHK-style peptides more product-friendly for serums and cosmetic formulas. That shifted interpretation toward topical delivery, concentration, and vehicle rather than injectable outcomes.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/17703734/>) [\[2\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Pal-AHK%22&limit=1>)

## Published research 16 citations

- [\[1\] **The effect of tripeptide-copper complex on human hair growth in vitro.** Arch Pharm Res, 2007 Jul. in vitro.](<https://pubmed.ncbi.nlm.nih.gov/17703734/>)
- [\[2\] **Drugs@FDA/openFDA query for Pal-AHK** U.S. Food and Drug Administration. database query.](<https://api.fda.gov/drug/drugsfda.json?search=%22Pal-AHK%22&limit=1>)
- [\[3\] **Compounding and the FDA: Questions and Answers** U.S. Food and Drug Administration. official guidance.](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>)
- [\[4\] **The 2026 List of Prohibited Substances and Methods** World Anti-Doping Agency. regulatory.](<https://ita.sport/resource/wada-2026-prohibited-list/>)
- [\[5\] **FDA Authority Over Cosmetics: How Cosmetics Are Not FDA-Approved, but Are FDA-Regulated** U.S. Food and Drug Administration. official guidance.](<https://www.fda.gov/cosmetics/cosmetics-laws-regulations/fda-authority-over-cosmetics-how-cosmetics-are-not-fda-approved-are-fda-regulated>)
- [\[6\] **Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act** U.S. Food and Drug Administration, 2026-05-14. regulatory.](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>)
- [\[7\] **Bulk Drug Substances Used in Compounding Under Section 503B of the FD&C Act** U.S. Food and Drug Administration, 2025-01-07. regulatory.](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>)
- [\[8\] **Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks** U.S. Food and Drug Administration, 2026-04-22. regulatory.](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)
- [\[9\] **European Medicines Agency medicines search** European Medicines Agency. official guidance.](<https://www.ema.europa.eu/en/medicines>)
- [\[10\] **MHRA Products search** Medicines and Healthcare products Regulatory Agency. official guidance.](<https://products.mhra.gov.uk/>)
- [\[11\] **Drug Product Database: Access the database** Health Canada. official guidance.](<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>)
- [\[12\] **Searching the Australian Register of Therapeutic Goods** Therapeutic Goods Administration. official guidance.](<https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg>)
- [\[13\] **Cosmetic Products Regulation** European Commission. official guidance.](<https://single-market-economy.ec.europa.eu/sectors/cosmetics/legislation_en>)
- [\[14\] **Making cosmetic products available to consumers in Great Britain** UK Office for Product Safety and Standards. official guidance.](<https://www.gov.uk/guidance/making-cosmetic-products-available-to-consumers-in-great-britain>)
- [\[15\] **Cosmetics regulatory information** Health Canada. official guidance.](<https://www.canada.ca/en/health-canada/services/consumer-product-safety/cosmetics/regulatory-information.html>)
- [\[16\] **Cosmetics and soap** Australian Industrial Chemicals Introduction Scheme. official guidance.](<https://www.industrialchemicals.gov.au/cosmetics-and-soap>)

[PepFlow library coverage](<https://pepflow.app/research/peptide-library/>)

## Quick facts

**Family**

Matrikine/copper tripeptide

**Tier**

D

**Evidence**

34% Limited

**Safety**

Limited Data

**FDA status**

Not Approved

**Topical 503A**

Not Listed

**Citations**

[16 citations](<https://pepflow.app/peptides/pal-ahk/#published-research>)

**Updated**

August 11, 2026

### Potential benefits

- Hair growth and dermal papilla cell proliferation
- Hair follicle cell survival signaling
- Skin appearance and collagen claims

### Common side effects

- Redness / irritation
- Scalp itch
- Dryness

### Also known as

- Palmitoyl tripeptide AHK
- Palmitoyl-Ala-His-Lys
- Pal-Ala-His-Lys
- AHK palmitate

## Related

- [Peptide Label Key](<https://pepflow.app/peptide-label-legend/>)
- [Pal-AHK dosage guide](<https://pepflow.app/peptides/pal-ahk/dosage/>)
- [PepFlow Library Statistics (2026) · 65 Profiles](<https://pepflow.app/research/peptide-library/>)
